No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
50 – 100
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
48 (estimated)
Sponsor
Herrick Medical LLC · Industry
Who this trial is looking for
This trial is looking for people aged 50 and older with mild to moderate dementia, including Alzheimer's disease, Lewy body dementia, or vascular dementia. Participants will use a pulsed electromagnetic treatment device at home three times a day for 120 days.
Are You a Good Fit for This Trial?
Must be takingCholinesterase inhibitorsMemantine
Rules you outEpilepsyFrontotemporal Dementia
You may be able to join if
I am 50 years old or older
I have been diagnosed with mild to moderate dementia
I have at least an eighth-grade education
I am post-menopausal if I am female
I have a Mini-Mental State Examination score between 16 and 26
I can provide consent or have someone to help me consent
I am able and willing to follow the study rules
I have been taking my current medications for at least 3 months
You may not be able to join if
I cannot provide consent and have no one to help me
I don't have someone available for study interviews
I have a history of seizures or epilepsy
I have Frontotemporal Dementia
I am taking medication that lowers seizure risk (other than blood thinners)
I am currently on anti-amyloid monoclonal antibodies
I have a serious psychiatric condition that affects my participation
I have had major surgery within the last 4 weeks
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Part…
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1\. Age ≥ 50 years 2.2. Patients diagnosed with mild to moderate AD/ADRD including Alzheimer's disease, Lewy body dementia, and Vascular dementia - defined as a global CDR of 0.5 or 1 at baseline.
3\. At least an eighth grade of educational achievement 4. If female, post-menopa…
Inclusion Criteria:
1\. Age ≥ 50 years 2.2. Patients diagnosed with mild to moderate AD/ADRD including Alzheimer's disease, Lewy body dementia, and Vascular dementia - defined as a global CDR of 0.5 or 1 at baseline.
3\. At least an eighth grade of educational achievement 4. If female, post-menopausal. 5. MMSE score between 16 and 26 (inclusive) 6. Capable of providing consent or having a surrogate (e.g., spouse, family member) capable of providing consent if participant lacks consent capacity 7. Able and willing to comply with the protocol 8. If the participant is receiving a cholinesterase inhibitor and/or memantine, such medication has been prescribed for at least 3 months prior to screening and the dose is stable for at least 60 days prior to screening (that dose needs to be maintained throughout the period of this study) 10. Physical clearance for study participation as evaluated by the clinician
Exclusion Criteria:
1. The patient lacks capacity to consent to study participation and no surrogate is available to provide consent
2. The patient does not have a study partner who would be available for interview
3. History of epileptic seizures or epilepsy
4. Has Frontotemporal Dementia
5. Currently taking medication that lowers the seizure threshold, excluding blood thinners
6. Is currently taking anti-amyloid monoclonal antibodies (past treatment is allowed if termination of treatment occurred at least 3 months prior to the baseline visit).
7. Presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
8. Severe agitation that would interfere with study procedures
9. Alcoholism or substance use disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
10. Major surgery (defined as any major abdominal, vascular or thoracic surgery requiring general anesthesia and resulting in a period of \>1 week hospitalization) within 4 weeks
11. Head anatomy that interferes with the fit of the treatment device
12. Participation in another clinical trial within the previous 30 days
13. Metal implants in the head, (i.e., cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth
14. Criteria to exclude participants from the blood draw study:
Any condition that may significantly increase risks associated with blood draws
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.